Related Experiment Videos
Business Ethics 101 for the biotech industry
1Department of Philosophy, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada. chrismac@ethicsweb.ca
Summary
Biotechnology firms confront unique corporate ethics issues in product safety, social responsibility, and governance. Addressing these requires interdisciplinary collaboration and industry-wide solutions for ethical benchmarks.
Area of Science:
- Biotechnology ethics
- Corporate social responsibility
- Business ethics
Background:
- Biotechnology companies face dual ethical challenges: bioethical concerns inherent in life sciences and corporate ethical issues stemming from their commercial nature.
- The corporate ethical dimension, particularly concerning commercial operations, remains under-explored in academic and media discourse.
- This paper addresses the gap by examining ethical issues specific to biotechnology companies as commercial entities.
Purpose of the Study:
- To analyze the distinct corporate ethical challenges faced by biotechnology companies.
- To focus on three key areas: product safety, corporate social responsibility, and corporate governance.
- To highlight the unique complexities within the biotechnology sector that exacerbate these ethical issues.
Main Methods:
- Conceptual analysis of ethical challenges in product safety, corporate social responsibility, and corporate governance within the biotechnology sector.
- Examination of the difficulties in establishing ethical benchmarks for a rapidly evolving and controversial field.
- Review of existing corporate governance failures (e.g., ImClone scandal) as cautionary examples.
Main Results:
- Biotechnology companies face unique hurdles in defining 'product safety' due to the contentious nature of 'harm' in life sciences.
- Implementing a stakeholder approach to corporate social responsibility is complex due to the wide range of stakeholders and controversies surrounding biotechnologies.
- Effective corporate governance requires robust practices for information, authority, and influence flow to prevent scandals.
Conclusions:
- Establishing ethical benchmarks in biotechnology is challenging due to the field's controversial and rapidly evolving nature.
- Recommendations include fostering interdisciplinary collaboration, building in-house expertise on corporate ethics, and leveraging industry associations for collective problem-solving.